S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Freshworks gets juiced on its AI customer engagement platform
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Freshworks gets juiced on its AI customer engagement platform
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Freshworks gets juiced on its AI customer engagement platform
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Freshworks gets juiced on its AI customer engagement platform
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
AP PHOTOS: Moscow hosts a fashion forum with designers from Brazil, China, India and South Africa

Medpace (MEDP) Stock Price, News & Analysis

$283.19
+1.74 (+0.62%)
(As of 12/8/2023 ET)
Compare
Today's Range
$279.16
$289.14
50-Day Range
$227.52
$283.19
52-Week Range
$167.00
$289.14
Volume
168,768 shs
Average Volume
177,272 shs
Market Capitalization
$8.69 billion
P/E Ratio
33.16
Dividend Yield
N/A
Price Target
$277.33

Medpace MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
2.1% Downside
$277.33 Price Target
Short Interest
Bearish
5.31% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.62
Upright™ Environmental Score
News Sentiment
1.19mentions of Medpace in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$137.72 M Sold Last Quarter
Proj. Earnings Growth
16.18%
From $8.65 to $10.05 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.40 out of 5 stars

Medical Sector

176th out of 940 stocks

Commercial Physical Research Industry

5th out of 13 stocks


MEDP stock logo

About Medpace Stock (NASDAQ:MEDP)

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

MEDP Stock Price History

MEDP Stock News Headlines

Medpace (NASDAQ:MEDP) Hits New 12-Month High at $289.14
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
Medpace Hldgs Insider Trades Send a Signal
Medpace Hldgs CEO Trades Company's Stock
CEO of Medpace Hldgs Sold $21.22M In Stock
Medpace Holdings Inc MEDP
See More Headlines
Receive MEDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Medpace and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
10/23/2023
Today
12/10/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/12/2024

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MEDP
Employees
5,200
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$277.33
High Stock Price Target
$289.00
Low Stock Price Target
$270.00
Potential Upside/Downside
-2.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$245.37 million
Pretax Margin
17.89%

Debt

Sales & Book Value

Annual Sales
$1.46 billion
Cash Flow
$8.64 per share
Book Value
$12.42 per share

Miscellaneous

Free Float
22,797,000
Market Cap
$8.69 billion
Optionable
Optionable
Beta
1.35
10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report














MEDP Stock Analysis - Frequently Asked Questions

Should I buy or sell Medpace stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" MEDP shares.
View MEDP analyst ratings
or view top-rated stocks.

What is Medpace's stock price target for 2024?

2 Wall Street research analysts have issued 12-month price targets for Medpace's stock. Their MEDP share price targets range from $270.00 to $289.00. On average, they expect the company's share price to reach $277.33 in the next twelve months. This suggests that the stock has a possible downside of 2.1%.
View analysts price targets for MEDP
or view top-rated stocks among Wall Street analysts.

How have MEDP shares performed in 2023?

Medpace's stock was trading at $212.41 on January 1st, 2023. Since then, MEDP shares have increased by 33.3% and is now trading at $283.19.
View the best growth stocks for 2023 here
.

When is Medpace's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 12th 2024.
View our MEDP earnings forecast
.

How were Medpace's earnings last quarter?

Medpace Holdings, Inc. (NASDAQ:MEDP) issued its quarterly earnings data on Monday, October, 23rd. The company reported $2.22 EPS for the quarter, topping the consensus estimate of $2.05 by $0.17. The business earned $492.50 million during the quarter, compared to the consensus estimate of $475.79 million. Medpace had a trailing twelve-month return on equity of 68.48% and a net margin of 15.33%. The business's quarterly revenue was up 28.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.05 EPS.

What guidance has Medpace issued on next quarter's earnings?

Medpace issued an update on its FY23 earnings guidance on Monday, October, 23rd. The company provided EPS guidance of $8.54-8.66 for the period, compared to the consensus earnings per share estimate of $8.39. The company issued revenue guidance of $1.87-1.89 billion, compared to the consensus revenue estimate of $1.87 billion.

What is August Troendle's approval rating as Medpace's CEO?

268 employees have rated Medpace Chief Executive Officer August Troendle on Glassdoor.com. August Troendle has an approval rating of 34% among the company's employees. This puts August Troendle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Medpace own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include NVIDIA (NVDA), Exact Sciences (EXAS), Block (SQ), Baidu (BIDU), JD.com (JD), Advanced Micro Devices (AMD), Bilibili (BILI), Alibaba Group (BABA), Cisco Systems (CSCO) and Intuitive Surgical (ISRG).

When did Medpace IPO?

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Who are Medpace's major shareholders?

Medpace's stock is owned by a number of retail and institutional investors. Top institutional investors include Fuller & Thaler Asset Management Inc. (2.08%), Invesco Ltd. (1.99%), Riverbridge Partners LLC (1.99%), Boston Trust Walden Corp (1.77%), Wellington Management Group LLP (1.37%) and Morgan Stanley (1.01%). Insiders that own company stock include Ashley M Keating, August J Troendle, August J Troendle, Jesse J Geiger, Kevin M Brady, Medpace Investors, Llc, Peter J O'malley, Robert O Kraft, Stephen P Ewald, Susan E Burwig, Tom C King and Wedbush Securities Inc.
View institutional ownership trends
.

How do I buy shares of Medpace?

Shares of MEDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:MEDP) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -